Drug intelligence / Profile preview

DWC202204

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral (inferred From Typical Administration Route For Small Molecules In Early-phase Trials; Not Explicitly Stated)

Overview

DWC202204 is an investigational small molecule drug developed by Daewoong Pharmaceutical. It is currently in early clinical development, with its primary evaluation focused on safety, pharmacokinetics, and drug-drug interactions when administered alone or in combination with other agents such as DWP16001 and DWC202205. The main therapeutic area under investigation appears to be metabolic disorders, specifically type 2 diabetes. As of now, the precise mechanism of action and molecular targets for DWC202204 have not been publicly disclosed[2][4].

Beyond the preview

Go deeper on DWC202204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202204.

Explore the full profile